Skip to content

Comparison of Physical Activity, Exercise Capacity, Quality of Life, Cognitive Function and Coronavirus Phobia Levels of Adult Cystic Fibrosis Patients With Healthy Individuals With Telerehabilitation

Comparison of Physical Activity, Exercise Capacity, Quality of Life, Cognitive Function and Coronavirus Phobia Levels of Adult Cystic Fibrosis Patients With Healthy Individuals With Telerehabilitation

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04673331
Enrollment
50
Registered
2020-12-17
Start date
2021-01-05
Completion date
2021-08-05
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic Fibrosis

Brief summary

The purpose of this study was to evaluate physical activity, exercise capacity, quality of life, cognitive status level and coronavirus phobia level of adult cystic fibrosis patients and compare with the findings of healthy subjects with teleconference during COVID-19 pandemic.

Detailed description

This study will be participated adult with cystic fibrosis and healthy individuals. Demographic information of individuals will be recorded in online video conference. Physical activity, exercise capacity and cognitive function levels will be measured during video conferencing.Then, the physical activity level, coronavirus phobia and quality of life of the participants will be evaluated subjectively with questionnaires through the Google forms.

Interventions

OTHERexercise capacity

3minute step test and 1minute sit to stand test used assessment of exercise capacity.

Sponsors

Hacettepe University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Being over 18 years old Having the ability to access the internet through a device (computer or mobile device) that enables video conferencing Giving consent on a voluntary basis

Exclusion criteria

* Severe comorbidity that limits mobilization or physical activity(orthopedic, cardiac or neurological condition) Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Physical Activity Level-International Physical Activity Questionnaire8 minutesPhysical activity level will be evaluated International Physical Activity Questionnaire- Short Form (IPAQ-SF). IPAQ short version asks spended time during sitting, walking, moderate and vigorous physical activities. The score is obtained by multiplying the minutes, days and metabolic equivalent values. According to these scores, physical activity levels are classified as "inactive", "minimally active" and "very active".
Coronavirus Phobia-Coronavirus-19 Phobia Scale5 minutesCOVID-19 phobia will be evaluated with Coronavirus-19 Phobia Scale (C19P-S) and total score ranges from 20-100. Lower scores mean better outcome.
Exercise Capacity15 minutesExercise capacity will be evaluated with 1-minute sit to stand test and 3-minute step test. Maximum heart rate, minimum saturation, count of step are record during the 3 minute step test. Number of sit to stand for 1 minute is recorded end of the 1 minute sit to stand test.
Weekly Average Steps2 minutesThe number of steps in the last week was recorded and averaged using the pedometer applications from the participants own smartphones. \<5000 steps/day sedentary 5000-7499 steps/day low active 7500-9999 steps/day somewhat active ≥10 000 steps/day active \>12 500 steps/day highly active

Secondary

MeasureTime frameDescription
Cognitive Function-Standardized Mini Mental State Examination5 minutesCognitive function evaluation will be Standardized Mini Mental State Examination (SMMSE). Scores less than 23 mean cognitive impairment.
Quality Of Life-Nottingham Health Profile10 minutesQuality of life will be evaluated with Nottingham Health Profile (NHP). This questionnaire categorizes are energy, pain, emotional reactions, sleep, social isolation, physical mobility, depression and anxiety. Lower scores mean better outcome.

Countries

Turkey (Türkiye)

Contacts

STUDY_DIRECTORNaciye Vardar Yağlı, PhD

Hacettepe University

PRINCIPAL_INVESTIGATORAydan Aslı Aksel

Hacettepe University

STUDY_CHAIREbru Damadoğlu, PhD

Hacettepe University

STUDY_CHAIRMerve Fırat, MSc

Hacettepe University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 1, 2026